Current status and future prospects of biomarkers in the diagnosis of hepatocellular carcinoma.

about

Current status and future prospects of biomarkers in the diagnosis of hepatocellular carcinoma.

Item

http://www.wikidata.org/entity/Q47920503

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Current status and future pros ...... s of hepatocellular carcinoma.

@en

Current status and future pros ...... s of hepatocellular carcinoma.

@nl

type

Item

label

Current status and future pros ...... s of hepatocellular carcinoma.

@en

Current status and future pros ...... s of hepatocellular carcinoma.

@nl

prefLabel

Current status and future pros ...... s of hepatocellular carcinoma.

@en

Current status and future pros ...... s of hepatocellular carcinoma.

@nl

P1476

Current status and future pros ...... is of hepatocellular carcinoma

@en

P2093

Chunhua Wang

http://www.w3.org/2001/XMLSchema#string

Liang Jin

http://www.w3.org/2001/XMLSchema#string

Liu Pei

http://www.w3.org/2001/XMLSchema#string

Qin Gao

http://www.w3.org/2001/XMLSchema#string

Yunsheng Zhao

http://www.w3.org/2001/XMLSchema#string

P2860

Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma

MicroRNA expression, survival, and response to interferon in liver cancer

Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma

Management of hepatocellular carcinoma: An update

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients

Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3

Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker.

P304

e361-e369

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5301/IJBM.5000299

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Fei Liao

P577

2017-10-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28967065

http://www.w3.org/2001/XMLSchema#string